Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal

JAMA Psychiatry

Volumn 70, Issue 5, 2013, Pages 522-533

  Cinciripini, Paul M ^a   Robinson, Jason D ^a   Karam Hage, Maher ^a   Minnix, Jennifer A ^a   Lam, Cho ^a   Versace, Francesco ^a   Brown, Victoria L ^a   Engelmann, Jeffrey M ^a   Wetter, David W ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; PLACEBO; VARENICLINE;

ADULT; ANGER; ANXIETY; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; EMOTION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COUNSELING; SMOKING; SMOKING CESSATION; SMOKING CESSATION PROGRAM; SUSTAINED DRUG RELEASE; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME;

EID: 84876898088     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2013.678     Document Type: Article

References (34)

1. Centers for Disease Control and Prevention (CDC). Quitting smoking among adults: United States, 2001-2010. MMWR Morb Mortal Wkly Rep. 2011;60(44):1513-1519.
2. Fiore MC, Jaen CR, Baker TB, et al. Treating Tobacco Use and Dependence: 2008 Update, Clinical Practice Guideline. Rockville, MD: Public Health Service, US Dept of Health and Human Services; 2008.
3. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation [update in Cochrane Database Syst Rev. 2012;(4):CD006103]. Cochrane Database Syst Rev. 2011;2:1-87.
4. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2007;1:CD000031.
5. Nides M, Glover ED, Reus VI, et al. Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis. Am J Health Behav. 2008;32(6):664-675.
6. Ascher JA, Cole JO, Colin JN, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry. 1995;56(9):395-401.
7. Damaj MI, Carroll FI, Eaton JB, et al. Enantioselective effects of hydroxymetabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Mol Pharmacol. 2004;66(3):675-682. (Pubitemid 39329267)
8. Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation. J Med Chem. 2005;48(10):3474-3477. (Pubitemid 40664098)
9. West R, Baker CL, Cappelleri JC, Bushmakin AG. Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. Psychopharmacology (Berl). 2008;197(3):371-377.
10. Hughes JR, Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry. 1986;43(3):289-294. (Pubitemid 16052281)
11. Gonzales D, Rennard SI, Nides M, et al; Varenicline Phase 3 Study Group. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):47-55.
12. Jorenby DE, Hays JT, Rigotti NA, et al; Varenicline Phase 3 Study Group. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):56-63.
13. US Food and Drug Administration. Information for healthcare professionals: varenicline (marketed as Chantix) and bupropion (marketed as Zyban, Wellbutrin, and generics). FDA alert. July 1, 2009. http://www.fda.gov/ Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm169986.htm. Accessed February 1, 2013.
14. Pocock S. Clinical Trials. New York, NY: John Wiley & Sons; 1983.
15. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-57.
16. Miller WR, Rollnick S. Motivational Interviewing: Preparing People for Change. New York, NY: Guilford Publications; 2002.
17. Fagerström KO. A comparison of psychological and pharmacological treatment in smoking cessation. J Behav Med. 1982;5(3):343-351. (Pubitemid 13197756)
18. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991;86(9):1119-1127.
19. Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol. 1988;54(6):1063-1070.
20. Welsch SK, Smith SS, Wetter DW, Jorenby DE, Fiore MC, Baker TB. Development and validation of the Wisconsin Smoking Withdrawal Scale. Exp Clin Psychopharmacol. 1999;7(4):354-361.
21. Ross CE, Mirowsky J. Components of depressed mood in married men and women: the Center for Epidemiologic Studies' Depression Scale. Am J Epidemiol. 1984;119(6):997-1004. (Pubitemid 14124215)
22. Kinnunen T, Doherty K, Militello FS, Garvey AJ. Depression and smoking cessation: characteristics of depressed smokers and effects of nicotine replacement. J Consult Clin Psychol. 1996;64(4):791-798. (Pubitemid 26274542)
23. Cappelleri JC, Bushmakin AG, Baker CL, Merikle E, Olufade AO, Gilbert DG. Confirmatory factor analyses and reliability of the modified Cigarette Evaluation Questionnaire. Addict Behav. 2007;32(5):912-923. (Pubitemid 46282288)
24. Brown RA, Burgess ES, Sales SD, Whiteley JA, Evans DM, Miller IW. Reliability and validity of a smoking timeline follow-back interview. Psychol Addict Behav. 1998;12(2):101-112. (Pubitemid 28294377)
25. Law KL, Stroud LR, LaGasse LL, Niaura R, Liu J, Lester BM. Smoking during pregnancy and newborn neurobehavior. Pediatrics. 2003;111(6, pt 1):1318-1323. (Pubitemid 36682265)
26. Hughes JR, Keely JP, Niaura RS, Ossip-Klein DJ, Richmond RL, Swan GE. Measures of abstinence in clinical trials: issues and recommendations [published correction appears in Nicotine Tob Res. 2003;5(4):603]. Nicotine Tob Res. 2003;5(1):13-25. (Pubitemid 36285465)
27. Cancer Therapy Evaluation Program, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) and Common Toxicity Criteria (CTC). 2010.http://ctep.cancer.gov/protocolDevelopment/electronic-applications/ ctc.htm. Accessed February 1, 2013.
28. Gibbons RD, Hedeker D, Waternaux C, Davis JM. Random regression models: a comprehensive approach to the analysis of longitudinal psychiatric data. Psychopharmacol Bull. 1988;24(3):438-443. (Pubitemid 19031632)
29. Gibbons R, Hedeker D, Elkin I, et al. Some conceptual and statistical issues in the analysis of longitudinal psychiatric data. Arch Gen Psychiatry. 1993;50:739-750.
30. Wu P, Wilson K, Dimoulas P, Mills EJ. Effectiveness of smoking cessation therapies: a systematic review and meta-analysis. BMC Public Health. 2006;6:e300. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1764891/. Accessed February 1, 2013.
31. Rennard S, Hughes J, Cinciripini PM, et al Flexible Quit Date Study Group. A randomized placebo-controlled trial of varenicline for smoking cessation allowing flexible quit dates. Nicotine Tob Res. 2012;14(3):343-350.
32. Moore TJ, Furberg CD, Glenmullen J, Maltsberger JT, Singh S. Suicidal behavior and depression in smoking cessation treatments. PLoS One. 2011;6(11): e27016. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3206890/. Accessed February 1, 2013.
33. Williams JM, Anthenelli RM, Morris CD, et al. A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2012;73(5):654-660.
34. Singh S, Loke YK, Spangler JG, Furberg CD. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ. 2011;183(12):1359-1366.